1. Homepage
  2. Equities
  3. Mexico
  4. Mexican Stock Exchange
  5. Genomma Lab Internacional, S.A.B. de C.V.
  6. News
  7. Summary
    LAB B   MX01LA010006

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.

(LAB B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Second Quarter Ended June 30, 2021

07/28/2021 | 01:16am EDT

Genomma Lab Internacional, S.A.B. De C.V. Announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was MXN 3,865.364 million compared to MXN 3,636.325 million a year ago. Operating income was MXN 741.990 million compared to MXN 714.855 million a year ago. Net income was MXN 379.203 million compared to MXN 360.817 million a year ago. For the half year, sales was MXN 7,413.015 million compared to MXN 6,970.861 million a year ago. Operating income was MXN 1,428.765 million compared to MXN 1,355.412 million a year ago. Net income was MXN 698.621 million compared to MXN 734.451 million a year ago.


© S&P Capital IQ 2021
All news about GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
04/28TRANSCRIPT : Genomma Lab Internacional, S.A.B. de C.V., Q1 2022 Earnings Call, Apr 28, 202..
CI
04/28TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on March 20,..
CI
04/27Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarte..
CI
04/27GENOMMA LAB INTERNACIONAL B DE C : Q1 2022 Earnings Release
PU
04/27GENOMMA LAB INTERNACIONAL B DE C : Application of IAS-36 and IFRS-13 (PIR) effects
PU
04/27GENOMMA LAB INTERNACIONAL B DE C : Aplicación de los efectos por IAS-36 e IFR-13 (PIR)
PU
04/19GENOMMA LAB INTERNACIONAL B DE C : 1Q-2022 Earnings Call Advisory
PU
04/15GENOMMA LAB INTERNACIONAL B DE C : PROXY 2022 – Genomma Lab informs the amount to be..
PU
04/15GENOMMA LAB INTERNACIONAL B DE C : PROXY 2022 – Genomma Lab informs the proposed ame..
PU
04/15GENOMMA LAB INTERNACIONAL B DE C : PROXY 2022 – Genomma Lab informs the amount to be..
PU
More news
Financials
Sales 2022 16 502 M 830 M 830 M
Net income 2022 2 108 M 106 M 106 M
Net Debt 2022 2 536 M 128 M 128 M
P/E ratio 2022 12,7x
Yield 2022 1,83%
Capitalization 20 402 M 1 027 M 1 027 M
EV / Sales 2022 1,39x
EV / Sales 2023 1,28x
Nbr of Employees 2 365
Free-Float 70,9%
Chart GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Duration : Period :
Genomma Lab Internacional, S.A.B. de C.V. Technical Analysis Chart | LAB B | MX01LA010006 | MarketScreener
Technical analysis trends GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 20,72 MXN
Average target price 25,85 MXN
Spread / Average Target 24,8%
EPS Revisions
Managers and Directors
Jorge Luis Brake Valderrama Chief Executive Officer
Antonio Zamora Galland Vice President-Administration & Finance
Rodrigo Alonso Herrera Aspra Chairman
Marco Sparvieri Chief Operating Officer & Executive Vice President
Juan Alonso Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.-3.54%1 050
JOHNSON & JOHNSON2.59%457 706
PFIZER, INC.-14.23%284 192
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY3.64%257 689